Cargando…

Hyperkalemia from preoperative non-steroidal anti-inflammatory drugs and angiotensin II receptor blockers in patients with nephropathy

Detalles Bibliográficos
Autores principales:	Song, Ho Kyung, Jang, Yeon, Nam, Jin Woo, You, Ju-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Anesthesiologists 2011
Materias:	Letter's to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249580/ https://www.ncbi.nlm.nih.gov/pubmed/22220235 http://dx.doi.org/10.4097/kjae.2011.61.6.533

Ejemplares similares

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis
por: Fukushima, Sakae, et al.
Publicado: (2023)

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
por: Sadjadi, Seyed Ali, et al.
Publicado: (2009)

Angiotensin II type 1 receptor blockers favorably affect renal angiotensin II and MAS receptor expression in patients with diabetic nephropathy
por: Ma, Ye-Ping, et al.
Publicado: (2020)

Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study
por: Espinel, Eugenia, et al.
Publicado: (2013)

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
por: Choi, Won Joon, et al.
Publicado: (2022)

Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review
por: Huang, Yunyu, et al.
Publicado: (2014)

Severe Hyponatremia Associated with the Use of Angiotensin II Receptor Blocker/thiazide Combinations
por: Kim, Da-Rae, et al.
Publicado: (2013)

Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy: A protocol for meta-analysis
por: Ma, Chang-e, et al.
Publicado: (2021)

A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
por: Pathak, Jahnavi V., et al.
Publicado: (2015)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Association Between Long-Term Use of Non-steroidal Anti-inflammatory Drugs and Hyperkalemia in Diabetic Patients
por: Sahil, FNU, et al.
Publicado: (2021)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series
por: Lee, Su Jin, et al.
Publicado: (2021)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy
por: Satoh, Minoru, et al.
Publicado: (2008)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study
por: Lapi, Francesco, et al.
Publicado: (2013)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Refractory hypotension during general anesthesia despite preoperative discontinuation of an angiotensin receptor blocker
por: Nabbi, Raha, et al.
Publicado: (2013)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
por: Orena, Stephen, et al.
Publicado: (2013)

Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration
por: Lee, Hyesung, et al.
Publicado: (2019)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Are Angiotensin II Receptor Blockers Really Safe From Aminotransferase Elevation or Drug-Induced Liver Injury?
por: Jang, Byoung Kuk
Publicado: (2022)

Stress-Dose Steroids: A Potential Therapeutic Option for Refractory Hyperkalemia
por: Zardoost, Pooya, et al.
Publicado: (2023)

Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats
por: Yoon, Namsik, et al.
Publicado: (2013)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_fume1uusvk8clkp2mb9hluvt9e